Approaches to the reactivation of hemoglobin F as a treatment for sickle cell disease.
DeSimone
Joseph
J
Department of Medicine, University of Illinois, USA.
D000107:Acetylation / Q000187:drug effects; D000755:Anemia, Sickle Cell / Q000628:therapy*; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018899:CpG Islands / Q000187:drug effects; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D019468:Disease Management; D004913:Erythrocytes, Abnormal; D005319:Fetal Hemoglobin / Q000096:biosynthesis* / Q000235:genetics; D020868:Gene Silencing / Q000187:drug effects; D005914:Globins / Q000096:biosynthesis / Q000235:genetics; D006451:Hemoglobin, Sickle / Q000235:genetics; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D010654:Phenylbutyrates / Q000494:pharmacology / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects
D006451:Hemoglobin, Sickle; D056572:Histone Deacetylase Inhibitors; D010654:Phenylbutyrates; D000077209:Decitabine; D005914:Globins; D005319:Fetal Hemoglobin; D001374:Azacitidine; D006918:Hydroxyurea